Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Lca-0061

Phase 1

LLycia Therapeutics, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

AtopicRecruiting

AtopicPhase 1

Recruiting

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Atopic

NCT07701954

Clinical

Trials by Indication[1]

Atopic1 trial

A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single Doses of LCA-0061 in Atopic Healthy Participants and Multiple Doses of LCA-0061 in Participants With Peanut Allergy

Recruiting·LLycia Therapeutics, Inc.·Phase 1·NCT07701954·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lca-0061. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Lca-0061. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Lycia Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: LLycia Therapeutics, Inc.

Related News